Chinnery, Patrick F., Bonnet, Marion, Cave, Alison, Hofer, Matthias P., Lamb, Alastair, McConkey, Glenn A., Medcalf, Nicholas, Smith, Stephen P., Tsakok, Teresa, Watson, Robert, Webster, Steve and You, Tao 2021. Choosing drugs for UK COVID-19 treatment trials. Nature Reviews Drug Discovery 10.1038/d41573-021-00203-7 |
Preview |
PDF
- Accepted Post-Print Version
Download (276kB) | Preview |
Preview |
PDF
- Supplemental Material
Download (327kB) | Preview |
Official URL: http://dx.doi.org/10.1038/d41573-021-00203-7
Abstract
In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results. A similar approach could be used for non-communicable diseases where treatment advances have been limited.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | Nature Research |
ISSN: | 1474-1776 |
Date of First Compliant Deposit: | 23 February 2022 |
Last Modified: | 14 Jun 2022 04:53 |
URI: | https://orca.cardiff.ac.uk/id/eprint/146157 |
Actions (repository staff only)
![]() |
Edit Item |